Financial Overview

• Underlying drug delivery business profitable

• Break-even and profitability predicted

• Adequate cash to break-even

• Market Cap approximately $500 million

• 30% held by Management & Directors

• Well supported research coverage

Previous slide

Next slide

Back to first slide

View graphic version